2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
327
Neoplasm Metastasis
40
Neoplasms
25
Advanced Breast Cancer
19
Ovarian Neoplasms
18
Carcinoma, Non-Small-Cell Lung
14
Endometrial Neoplasms
11
Prostatic Neoplasms
10
Hereditary Sensory and Autonomic Neuropathies
10
Triple Negative Breast Neoplasms
8
Colorectal Neoplasms
6
Breast Cancer Metastatic
6
Uterine Cervical Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Recurrence
5
Multiple Endocrine Neoplasia Type 1
5
Carcinoma, Ovarian Epithelial
5
Breast Diseases
5
Neoplasms by Site
4
Stomach Neoplasms
3
Small Cell Lung Carcinoma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Fallopian Tube Neoplasms
3
Carcinoma, Lobular
3
Breast Neoplasm Female
3
Uterine Neoplasms
2
Pancreatic Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Interventions
Carboplatin
71
Paclitaxel
49
Radiotherapy
44
Pemetrexed
42
Cisplatin
41
Bevacizumab
39
Gemcitabine
27
Docetaxel
27
Erlotinib Hydrochloride
23
Gefitinib
18
pembrolizumab
14
Taxes
13
Vinorelbine
10
Cetuximab
10
Radiation
8
Nivolumab
8
Magnetic Resonance Spectroscopy
8
capmatinib
7
Radiosurgery
7
Platinum
7
Etoposide
7
Surgical Procedures, Operative
6
Radiotherapy, Conformal
6
Mastectomy, Segmental
6
ceritinib
5
aflutinib
5
Specimen Handling
5
Neoadjuvant Therapy
5
Cyclophosphamide
5
Biopsy
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
Fulvestrant
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled